Published in Mol Immunol on November 01, 1986
Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med (1998) 6.36
Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol (2001) 6.32
Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med (2001) 5.71
Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med (1999) 5.55
Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol (1999) 4.87
Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol (1999) 4.53
Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity (1996) 2.96
Stimulation of lymphocytes by autologous leukaemic cells in acute leukaemia. Nature (1969) 2.75
Antibody-induced redistribution of HL-A antigens at the cell surface. Eur J Immunol (1972) 2.58
A macrophage Fc gamma receptor and the mast cell receptor for IgE share an identical subunit. Nature (1989) 2.55
Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet (2004) 2.55
Immunoreceptor tyrosine-based inhibition motifs. Immunol Today (1997) 2.46
Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science (1992) 2.41
The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem (2001) 2.33
FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity (2002) 2.31
Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res (1999) 2.23
The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity (1995) 2.12
TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol (1999) 2.05
Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GA2LEN project. Allergy (2006) 1.84
Cell-mediate cytotoxicity in vitro of human lymphocytes against a tissue culture melanoma cell line (igr3). J Immunol (1975) 1.82
Independence of H-2K and H-2D antigenic determinants on the surface of mouse lymphocytes. J Exp Med (1973) 1.76
Bacteria-induced neo-biosynthesis, stabilization, and surface expression of functional class I molecules in mouse dendritic cells. Proc Natl Acad Sci U S A (1998) 1.74
Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet (1993) 1.72
Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. J Natl Cancer Inst (1998) 1.71
Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest (1995) 1.70
The cell biology of antigen presentation in dendritic cells. Curr Opin Immunol (2001) 1.63
Deficient peptide loading and MHC class II endosomal sorting in a human genetic immunodeficiency disease: the Chediak-Higashi syndrome. J Cell Biol (1998) 1.60
Tyrosine-containing motif that transduces cell activation signals also determines internalization and antigen presentation via type III receptors for IgG. Nature (1992) 1.60
The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet (2009) 1.59
The invariant chain is required for intracellular transport and function of major histocompatibility complex class II molecules. J Exp Med (1994) 1.59
Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet (2001) 1.58
Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev (2011) 1.55
Independence of HL-A antigens and immunoglobulin determinants on the surface of human lymphoid cells. Eur J Immunol (1972) 1.52
Relationship between the EBV-associated membrane antigen on Burkitt lymphoma cells and the viral envelope, demonstrated by immunoferritin labelling. Int J Cancer (1971) 1.50
Characterization and function of T cell Fc gamma receptor. Immunol Rev (1981) 1.50
Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J Immunol (2001) 1.48
T-cell hybrids bear Fcgamma receptors and secrete suppressor immunoglobulin binding factor. Nature (1979) 1.47
Soluble Fc gamma receptors. J Leukoc Biol (1993) 1.45
Suppression of in vitro antibody synthesis by immunoglobulin-binding factor. J Exp Med (1975) 1.37
Expression of high-affinity binding of human immunoglobulin E by transfected cells. Science (1989) 1.36
Highly resolved chemical imaging of living cells by using synchrotron infrared microspectrometry. Proc Natl Acad Sci U S A (1998) 1.36
Tumor-derived exosomes: a new source of tumor rejection antigens. Vaccine (2002) 1.33
Isolation and characterization of cDNAs coding for the beta subunit of the high-affinity receptor for immunoglobulin E. Proc Natl Acad Sci U S A (1988) 1.32
p53 antibodies in patients with various types of cancer: assay, identification, and characterization. Clin Cancer Res (1995) 1.31
Ii chain controls the transport of major histocompatibility complex class II molecules to and from lysosomes. J Cell Biol (1997) 1.30
Fc epsilon receptor I-associated lyn-dependent phosphorylation of Fc gamma receptor IIB during negative regulation of mast cell activation. J Immunol (1998) 1.28
Mast cell membrane antigens and Fc receptors in anaphylaxis. II. Functionally distinct receptors for IgG and for IgE on mouse mast cells. Cell Immunol (1980) 1.27
Biochemical analysis of glucocorticoid-induced inhibition of IgE-mediated histamine release from mouse mast cells. J Immunol (1982) 1.27
Absence of allogeneic restriction in human T-cell-mediated cytotoxicity to Epstein-Barr virus-infected target cells. Demonstration of an HLA-linked control at the effector level. J Exp Med (1979) 1.27
Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer (1995) 1.25
Role of B cell receptor Ig alpha and Ig beta subunits in MHC class II-restricted antigen presentation. Immunity (1995) 1.25
Structural bases of Fc gamma receptor functions. Immunol Rev (1992) 1.23
The identification of monoclonal class switch variants by sib selection and an ELISA assay. J Immunol Methods (1984) 1.21
Role of associated gamma-chain in tyrosine kinase activation via murine Fc gamma RIII. EMBO J (1992) 1.20
Isotype regulation of antibody production: T-cell hybrids can be selectively induced to produce IgG1 and IgG2 subclass-specific suppressive immunoglobulin-binding factors. Proc Natl Acad Sci U S A (1983) 1.19
syk protein tyrosine kinase regulates Fc receptor gamma-chain-mediated transport to lysosomes. EMBO J (1998) 1.19
Methods and limitations of 'clumped' CO2 isotope (Delta47) analysis by gas-source isotope ratio mass spectrometry. J Mass Spectrom (2009) 1.17
Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant (2008) 1.17
Vimentin filaments in fibroblasts are a reservoir for SNAP23, a component of the membrane fusion machinery. Mol Biol Cell (2000) 1.15
Suppression of mitogen-induced peripheral B cell differentiation by soluble Fc gamma receptors released from lymphocytes. Eur J Immunol (1980) 1.14
Chemical imaging of nucleic acids, proteins and lipids of a single living cell. Application of synchrotron infrared microspectrometry in cell biology. Cell Mol Biol (Noisy-le-grand) (1998) 1.13
A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. EMBO J (1998) 1.13
Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer (1994) 1.12
Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int J Cancer (1999) 1.11
The Src homology 2 domain of Vav is required for its compartmentation to the plasma membrane and activation of c-Jun NH(2)-terminal kinase 1. J Exp Med (2000) 1.11
Macrophage inflammatory protein-1alpha is induced by human immunodeficiency virus infection of monocyte-derived macrophages. Blood (1996) 1.11
T cell hybridomas coexpressing Fc receptors (FcR) for different isotypes. II. IgA-induced formation of suppressive IgA binding factor(s) by a murine T hybridoma bearing Fc gamma R and Fc alpha R. J Immunol (1983) 1.10
Immunoglobulin-binding factor present on and produced by thymus-processed lymphocytes (T cells). Cell Immunol (1974) 1.10
HLA-DM is localized to conventional and unconventional MHC class II-containing endocytic compartments. Immunity (1996) 1.09
The role of the Fc receptor (FcR) of thymus-derived lymphocytes. II. Presence of FcR on suppressor cells and direct involvement in suppression. Eur J Immunol (1977) 1.09
Involvement of the ras-like GTPase rab3d in RBL-2H3 mast cell exocytosis following stimulation via high affinity IgE receptors (Fc epsilonRI). J Immunol (1997) 1.08
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother (2010) 1.08
Reconstituted killer cell inhibitory receptors for major histocompatibility complex class I molecules control mast cell activation induced via immunoreceptor tyrosine-based activation motifs. J Biol Chem (1997) 1.08
Interferon enhances the expression of Fc gamma receptors. J Immunol (1980) 1.08
The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. J Immunol (2000) 1.07
Induction of tolerance by exosomes and short-term immunosuppression in a fully MHC-mismatched rat cardiac allograft model. Am J Transplant (2006) 1.07
Differential association of phosphatases with hematopoietic co-receptors bearing immunoreceptor tyrosine-based inhibition motifs. Eur J Immunol (1997) 1.07
Imaging capabilities of synchrotron infrared microspectroscopy. Faraday Discuss (2004) 1.06
Relationship between HL-A antigens and beta-2-microglobulin as studied by immunofluorescence on the lymphocyte membrane. J Exp Med (1974) 1.06
Monoclonal antibodies reveal the structural basis of antibody diversity. Science (1983) 1.06
Interleukin-18: biological properties and clinical implications. Eur Cytokine Netw (2000) 1.06
Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia (2010) 1.06
Soluble Fcgamma receptor type III (FcgammaRIII, CD16) triggers cell activation through interaction with complement receptors. J Immunol (1996) 1.05